Zimbabwe has rejected a substantial American health deal valued at $367m (£272m) spanning five years due to the United States' demand for confidential biological samples.
The decision came to light after a government memo dated December was leaked, revealing that President Emmerson Mnangagwa felt the deal was "skewed".
A government representative later stated that the United States was seeking biological samples for scientific study and profit while was unwilling to share the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate process of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had provided more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for continued negotiations to secure a agreement acceptable to both sides so the nation's vital HIV programme can proceed.
Wider Background
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a high court blocked a similar deal with the US following legal challenges were raised about the security of citizens' health data.
Since returning to office last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had managed aid for the US government, but Trump stated its spending was "wasteful" and his administration was seeking direct bilateral agreements to enhance openness and responsibility.
According to statements, Sixteen nations in Africa have so far signed similar health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
The funds for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership would have delivered immense advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy via American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data for a long time, without any corresponding assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"Put simply, our nation would provide the basic resources for medical research with no assurance that the resulting innovations would be accessible to our citizens if a future health crisis emerge."
Sovereignty and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining structures already set up through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework designed to deal with potential pandemics.
"This framework is designed to ensure that when a country provides its samples, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome further discussions with our US partners on how subsequent co-operation might be designed in a way that honours the independence and dignity of both nations."
Medical Community Response
A leading public health body said it understood the official position, but suggested that negotiations should continue since a large portion of the nation's HIV programmes relied on foreign aid.
"In cases where technical issues exist, including those involving information security or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," the group commented.
The halted deal highlights the continuing debate between receiving crucial foreign assistance and protecting local interests in an ever more interconnected world.